Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maraviroc advisory committee

Executive Summary

FDA's Antiviral Drugs Advisory Committee will meet April 24 to review Pfizer's potential first-in-class HIV therapy maraviroc, according to a notice in the Federal Register Feb. 7. Pfizer will market the CCR5 antagonist candidate with Monogram's co-receptor tropism assay Trofile to identify patients who are most likely to respond to the drug class (1"The Pink Sheet" Dec. 18, 2006, p. 11). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...
Advertisement

Related Content

Pfizer Maraviroc Assay In HIV Is Model For Personalized Medicine, Firm Says
Pfizer Maraviroc Assay In HIV Is Model For Personalized Medicine, Firm Says
Advertisement
UsernamePublicRestriction

Register

PS048020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel